Results 141 to 150 of about 1,126,910 (189)
Some of the next articles are maybe not open access.
[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer].
Zhonghua nan ke xue = National journal of andrology, 2009Cyclooxygenase-2 (Cox-2) is over-expressed in prostate cancer (PCa) and involved in its development and progression by facilitating inflammatory response, reducing cell apoptosis, increasing angiogenesis and damaging DNA oxidation. Selective Cox-2 inhibitors suppress PCa growth through various channels and therefore have a promising application value ...
Song, Xu, Jian-Ping, Gao, Wen-Quan, Zhou
openaire +1 more source
Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry, 2007Cyclooxygenase is a key enzyme responsible for metabolisation of arachidonic acid into prostaglandins and thromboxane. This enzyme is the target of non steroidal anti-inflammatory drugs (NSAIDs), used against inflammation and pain. The inducible COX-2 was associated with inflammatory conditions, whereas the constitutive form (COX-1) was responsible for
J. Dogné +4 more
openaire +4 more sources
Cardiovascular effects of cyclooxygenase-2 inhibitors
Current Opinion in Internal Medicine, 2008Arthritis and musculoskeletal disorders are highly prevalent and management often involves the use of nonsteroidal antiinflammatory drugs. Cyclooxygenase-2 enzyme inhibitors are newer selective nonsteroidal antiinflammatory drugs that purport to exhibit less gastrointestinal toxicity than traditional nonsteroidal antiinflammatory drugs.
openaire +2 more sources
Cyclooxygenase-2–specific inhibitors: are they safe?
The American Journal of Medicine, 2001The basic tenet of the cyclooxygenase-2 (COX-2) hypothesis rests on the fact that sparing of inhibition of COX-1 should result in greater safety than if both COX isoforms are inhibited. This increase in safety should be most evident in those organs and tissues in which COX-1 alone has important, necessary physiologic functions (e.g., the stomach and ...
openaire +2 more sources
Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design, 2003Cyclooxygenase-1 (COX-1) derived eicosanoids promote gastroprotective mucosal defenses and induce platelet aggregation. By sparing COX-1, COX-2 specific inhibitors provide effective anti-inflammatory and analgesic activity while substantially reducing the risk of peptic ulcer disease and GI bleeding compared to dual COX inhibitors (traditional NSAIDs).
openaire +2 more sources
Selective cyclooxygenase-2 inhibitors
La Presse Médicale, 2005Resume Objectifs L’utilisation des inhibiteurs selectifs de la cyclo-oxygenase 2 (coxibs) est actuellement contestee, en particulier en raison des risques cardiovasculaires. Peu de travaux ont evalue leurs conditions reelles d’utilisation. Cette etude avait pour buts de mesurer l’evolution des conditions reelles d’utilisation des coxibs en France et
Guy-Robert Auleley +3 more
openaire +1 more source
Selective inhibitors of cyclooxygenase-2
Expert Opinion on Therapeutic Patents, 1997Prostaglandins (PGs) produced by the inducible enzyme cyclooxygenase-2 (COX-2) are important mediators of pain and inflammation. In animals, selective inhibitors of COX-2 have been shown to be anti-inflammatory without typical non-steroidal anti-inflammatory drug (NSAID) side-effects. Research directed towards the identification of potent and selective
openaire +1 more source